SUMMARY: The most recent Bayer information about the YAZ / Yasmin litigation comes from its corporate Interim Report for First Quarter of 2015:
Yasmin™/yaz™: As of April 20, 2015, the number of claimants in the pending lawsuits and claims in the United States totaled about 4,600 (excluding claims already settled)….
As of April 20, 2015, Bayer had reached agreements, without admission of liability, to settle approximately 9,600 claims in the u.s. for venous clot injuries (deep vein thrombosis or pulmonary embolism) for a total amount of about us$1.92 billion. Bayer will continue to consider the option of settling such claims after a case-specific analysis of medical records. At present, about 1,000 such claims are under review.
In comparison, from Bayer’s 2014 Annual Report:
• As of January 31, 2015, the number of claimants in the pending lawsuits and claims in the United States totaled about 5,000 (excluding claims already settled).
• As of January 31, 2015, Bayer had reached agreements, without admission of liability, to settle approximately 9,500 claims in the U.S. for venous clot injuries (deep vein thrombosis or pulmonary embolism) for a total amount of about US$1.9 billion.
• At present, about 2,000 such claims are under review….
We will continue to report periodically on the entire Beyaz / Safyral / YAZ / Yasmin / Gianvi / Ocella drug injury litigation, as we have been doing since 2009 when the first lawsuits against Bayer were filed.
[Read this article in full at original source]_______________________________________________________________________
Beyaz/Safyral/YAZ/Yasmin/Ocella/Gianvi
Free Case Evaluation
Strictly Confidential, No Obligation.
______________________________________________________________________